Accessibility Menu
Compass Therapeutics logo

Compass Therapeutics

(NASDAQ) CMPX

Current Price$2.06
Market Cap$369.18MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-76%
5 Year-59%
1 Year-35%
1 Month+0%
Compass Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 2.052026-07-17
Compass Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-12.02%USD 2.332026-07-10
1 month+0%USD 2.052026-06-17
3 month-65.83%USD 6.002026-04-17
Year to date-61.82%USD 5.372025-12-31
1 year-34.92%USD 3.152025-07-17
3 year-27.3%USD 2.822023-07-18
5 year-59%USD 5.002021-07-16
Since inception-75.88%USD 8.502021-04-05

Compass Therapeutics Financials at a Glance

Market Cap

$369.18MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$68.17M

EPS (TTM)

-$0.41

P/E Ratio

-4.98

Dividend

$0.00

Beta (Volatility)

1.01 (Average)

Price

$2.06

Volume

79,161

Open

$2.06

Previous Close

$2.06

Daily Range

$2.03 - $2.12

52-Week Range

$1.61 - $6.88

Estimated Earnings Date

Aug 10, 2026

CMPX News

BuyAlert-Green.png

Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing

Jake LerchMar 2, 2026
Foolcom-Featured.png

Compass Therapeutics Posts Wider Q2 Loss

Motley Fool Markets TeamAug 11, 2025

CMPX: Motley Fool Moneyball Superscore

59

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for cancer and other diseases. By targeting angiogenesis, immune modulation, and tumor growth, Compass aims to address significant unmet needs in oncology and immunology.

Products and Services

Tovecimig: A bispecific antibody targeting DLL4 and VEGF-A, designed to disrupt tumor angiogenesis.

CTX-471: An antibody that targets CD137, enhancing immune system activation against tumors.

CTX-8371: A bispecific antibody targeting PD-1 and PD-L1, potentially improving checkpoint inhibition.

CTX-10726: A bispecific antibody combining PD-1 and VEGF-A targeting, currently in preclinical development.

What Makes Compass Therapeutics, Inc. Special

Compass Therapeutics distinguishes itself through its proprietary StitchMabs™ platform, which enables the development of multi-specific antibodies for enhanced targeting of disease mechanisms. This innovative approach allows Compass to potentially offer more effective and safer therapies than its competitors.

Five Things You Need to Know

The company's current portfolio includes four key products targeting cancer, with tovecimig being the most advanced in clinical trials.

Focuses on combining angiogenesis inhibition and immune modulation for effective anti-tumor therapies.

The leadership team has extensive experience in biopharmaceutical development, guiding Compass's strategic vision.

Plans include advancing their clinical pipeline and forming strategic partnerships for growth and market capture.

The StitchMabs™ platform underlies their technological edge in creating next-generation antibody therapies.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

39

CEO

Thomas J. Schuetz, MD, PhD

Website

www.compasstherapeutics.com

Headquarters

Boston, MA 02135, US

CMPX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-39.75%

Return on Capital

-35.25%

Return on Assets

-33.23%

Earnings Yield

-20.08%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$369.18MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

180.09M

Volume

79.16K

Avg. Volume

7.89M

Financials (TTM)

Gross Profit

-$738.00K

Operating Income

-$75.17M

EBITDA

-$67.05M

Operating Cash Flow

-$53.20M

Capital Expenditure

-$89.00K

Free Cash Flow

-$53.29M

Cash & ST Invst.

$194.69M

Total Debt

$9.79M

Compass Therapeutics Performance Analysis

Compass Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 850,000N/A
20252025-12-31USD 0N/A
Compass Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Compass Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.37-54.2%
20232023-12-31USD -0.33-10.3%
20242024-12-31USD -0.367.4%
20252025-12-31USD -0.4217.3%
Compass Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-16.7%
Q32025-09-3028.6%
Q42025-12-3115.0%
Q12026-03-31-17.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$368.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$369.18MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$9.47M

N/A

Employees

39

N/A

Net Income

-$18.32M

-10.1%

EBITDA

-$17.95M

-10.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$194.69M

+72.8%

Total Debt

$9.79M

+53.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$8.42M

+34.2%

Short Term Debt

$1.37M

+1159.6%

Return on Assets

-33.23%

N/A

Return on Invested Capital

-38.57%

N/A

Free Cash Flow

-$17.35M

-31.2%

Operating Cash Flow

-$17.27M

-30.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BCYCBicycle Therapeutics plc
$4.21+0.72%
OCGNOcugen, Inc.
$1.36-0.73%
FULCFulcrum Therapeutics, Inc.
$3.65+4.29%
FDMT4D Molecular Therapeutics, Inc.
$10.99+1.38%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
NFLXNetflix
$68.95-0.07%
NOKNokia
$10.12-0.03%

Questions About CMPX

What is the current price of Compass Therapeutics?

Compass Therapeutics is trading at $2.06 per share.

What is the 52-week range for Compass Therapeutics?

Over the past 52 weeks, Compass Therapeutics has traded between $1.61 and $6.88.

How much debt does Compass Therapeutics have?

As of the most recent reporting period, Compass Therapeutics reported total debt of $9.79M.

How much cash does Compass Therapeutics have on hand?

Compass Therapeutics reported $55.17M in cash and cash equivalents in its most recent financial results.

What is Compass Therapeutics’s dividend yield?

Compass Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services